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Purpose:  To  evaluate  the  relationship  of apparent  diffusion  coefﬁcient  (ADC)  values  of  renal  parenchyma
with  chronic  kidney  disease  (CKD)  stage  and  serum  creatinine  levels.
Materials  and  methods:  One  hundred  and  ten  patients  who  had  undergone  magnetic  resonance  imaging
of the  upper  abdomen  for different  reasons  were  retrospectively  studied.  A  region  of  interest  (ROI)  was
placed  on the  renal  parenchyma  for measurement  of ADC  values  of  both  kidneys,  without  any  preference
for  cortex  or medulla.  Three  circular  ROIs  were  placed-one  each  in  the upper  pole,  interpolar  region  and
lower  pole  of both  kidneys.  The  mean  ADC  values  were  recorded  for  each  patient  and  the  relationship
between  ADC  values  and  stage  of CKD  and  serum  creatinine  levels  were  evaluated.
Results: Statistically  signiﬁcant  difference  was determined  between  the ADC  values of  the  cases  according
to  CKD  stages  (p < 0.001).  Paired  comparisons  performed  to determine  the group  that  caused  the differ-
ence  revealed  that  median  ADC  values  of  healthy  subjects  who  formed  the control  group  was statistically
signiﬁcantly  higher  than that  of  the  cases  with  stage  3, stage  4  and  stage  5 CKD (p: 0.008;  p: 0.008;  and
p:  0.002,  respectively).  Sensitivity  and  speciﬁcity  were  found  to  be  75.44%  and  69.81%,  respectively  in
detecting  stage  3, stage  4 and  stage  5 CKD  among  the cases  with  ADC  values  of 1151  and  lower.
Conclusion:  ADC  values  can  play  a role  in the  evaluation  of renal  dysfunction.  However,  population-and
protocol-based  cut-off  ADC  values  are  needed  to  identify  renal  dysfunction  and  to distinguish  between
different  stages  of CKD.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Chronic kidney disease (CKD) is being recognized as a world-
ide leading public health problem [1]. Along with the high cost
nd poor outcomes, there is a rising incidence and prevalence of
idney failure all over the world [2]. Serum markers such as cre-
tinine and blood urea nitrogen level, and estimated glomerular
ltration rate (eGFR) are useful parameters for estimating renal
unction [3]; however, blood tests depend on age and body mass
ndex and cannot be used to evaluate single kidney function.
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Because of the limitations of serum markers, imaging techniques
gain importance in the evaluation of renal function [4]. Functional
renal imaging methods, such as diffusion-weighted magnetic res-
onance imaging (DW-MRI), which is used to show the Brownian
motion of the spins in biological tissues and to distinguish between
normal and abnormal structures of tissues better, has been shown
to be a promising technique in the evaluation of renal function [5].
The apparent diffusion coefﬁcient (ADC) is a quantitative param-
eter calculated from DW-MRI images, and represents the water
diffusion in the extracellular and extravascular space and capillary
perfusion [6]. To date, there have been few studies investigating the
relationship between ADC values and different stages of CKD. Vari-
ous cut off ADC values have been identiﬁed by different researchers
[7–11].
The aim of our study was to retrospectively evaluate the rela-
tionship of ADC values of renal parenchyma with CKD stage and
serum creatinine levels.
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. Materials and methods
One hundred and ten (45 men, 65 women; mean age
1.58 ± 13.25 years; range, 19–85 years) patients who had under-
one abdominal MRI  for different reasons and whose serum
reatinine levels had been measured within two weeks from
maging between September 2014 and February 2015, were ret-
ospectively studied. The study protocol was approved by the
thics Committee of our hospital. Patients were classiﬁed into
ve stages of CKD based on disease severity, according to the
/DOQI CKD (kidney disease outcomes quality initiative) classiﬁca-
ion [12]. Stage 1: eGFR; ≥90 mL/min/1.73 m2 (kidney damage with
ormal or increased eGFR). Stage 2: eGFR; 60–89 mL/min/1.73 m2
kidney damage with a mild reduction in eGFR). Stage 3: eGFR;
0–59 mL/min/1.73 m2 (moderate reduction in eGFR). Stage 4:
GFR; 15–29 mL/min/1.73 m2 (severe reduction in eGFR). Stage 5:
GFR; < 15 mL/min/1.73 m2 (kidney failure). GFR was calculated
sing Japanese eGFR equation based on serum creatinine level:
GFR (mL/min/1.73 m2) = 194 × plasma creatinine−1.094 × age−0.287
×0.739 if female) [13]. All data including demographic infor-
ation, clinical, and laboratory ﬁndings were obtained from the
edical records of the patients. Patients were excluded from the
tudy if they had a single kidney, severe parenchymal atrophy, large
olid/cystic lesion in the kidney, autosomal dominant polycystic
idney disease, acute renal failure, unacceptable image quality, and
nsufﬁcient medical information.
All MRI  examinations were performed with a 1.5-T scan-
er (Avanto, Siemens Healthcare, Germany). All MRI  scans were
btained with the following parameters: Repetition time (TR);
580 ms,  echo time (TE); 60 ms,  slice thickness; 1–5 mm,  receiver
andwidth; 1158 kHz/pixel, ﬁeld of view (FOV); 40 cm,  matrix size;
64 × 159. All MRI  scans were independently evaluated by four
xperienced radiologists who were blinded to the clinical and lab-
ratory ﬁndings. ADC value of the kidneys was  calculated with
iffusion gradient b-values of 0 and 400 s/mm2. In the axial ADC
ap, a region of interest (ROI) was placed for measurement of ADC
alues on the renal parenchyma of both kidneys, without any pref-
rence for cortex or medulla (Fig. 1). Three circular ROIs of size
 cm2 were placed-one each at the upper pole, interpolar region,
nd lower pole of both kidneys—and 6 total ROIs from bilateral
idneys were averaged for each patient. Creatinine was  calculated
sing the standard laboratory assay. The mean ADC values were
ecorded for each patient and the relationship of ADC values with
KD stage and serum creatinine levels were evaluated.
Number Cruncher Statistical System (NCSS) 2007 (Kaysville,
tah, USA) program was used for statistical analysis. Descrip-
ive statistics are presented as mean, standard deviation, median,
inimum, maximum, frequency and ratios. Kruskal–Wallis test
as used to compare the variables between the groups, and
able 1
DC values of different stages of CKD patients and healthy group.
ADC
Min–max Mean ± SD 
Healthy group 1082–1508 1237.13 ± 134.15 
Stage 1 1092–1212 1178.00 ± 50.39 
Stage 2 936–1484 1198.94 ± 98.34 
Stage 3 991–1465 1139.16 ± 97.61 
Stage 4 839–1272 1021.00 ± 149.95 
Stage 5 880–1163 1009.38 ± 123.58 
1: First quartile.
3: Third quartile.
a Kruskal–Wallis test.
b Mann–Whitney U test.
* p < 0.05.
** p < 0.01.Fig. 1. ADC map of a patient. Sample of measurement technique.
Mann–Whitney U test was used as post-hoc test. ROC curve analy-
sis and sensitivity, speciﬁcity, PPV, NPV and accuracy values were
used to determine cut-off values. Spearman’s rank correlation coef-
ﬁcient was used to determine the association between variables.
Signiﬁcance was  evaluated at a p value <0.05.
3. Results
ADC values of the cases ranged between 839 and 1508 units,
with a mean ADC value of 1156.34 ± 122.909 units. Of  the cases,
13.6% (n = 15) were healthy subjects; whereas, 4.5% (n = 5) had stage
1, 30.0% (n = 33) had stage 2, 39.1% (n = 43) had stage 3, 5.5% (n = 6)
had stage 4, and 7.3% (n = 8) had stage 5 CKD. Statistically signiﬁ-
cant difference was  determined between ADC  values of the cases
according to CKD stages (p < 0.001). Paired comparisons performed
to determine the group that caused the difference revealed that
median ADC values of healthy subjects who constituted the control
group was statistically signiﬁcantly higher than that of the cases
with stage 3, stage 4 and stage 5 CKD (p: 0.008; p: 0.008; and p:
0.002, respectively). It was found that median ADC values of the
cases with stage 1 CKD were statistically signiﬁcantly higher than
that of the cases with stage 5 CKD (p: 0.013), and the median ADC
values of the cases with stage 2 CKD were signiﬁcantly higher than
ap bPost-hoc
Median (Q1–Q3)
1219 (1126–1285) <0.001** H > G3**, G4**, G5**
1199 (1133.5–1212) G1 > G5*
1207 (1130.5–1251) G2 > G3**,  G4**, G5**
1119 (1071–1167) G3 > G4*, G5*
1008 (904.25–1122.75)
998.5 (892.5–1127.75)
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Table 2
Relationship between serum creatinine level and ADC values.
Creatinine
ADC R −0.316
P 0.001**
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** p < 0.01.
hat of the cases with stage 3, stage 4 and stage 5 CKD (p: 0.002;
: 0.008; p: 0.001, respectively). Median ADC values of the cases
ith stage 3 CKD were signiﬁcantly higher than that of the cases
ith stage 4 and stage 5 CKD (p: 0.025 and p: 0.031, respectively).
o statistically signiﬁcant difference was determined between the
ther groups in terms of ADC values (p > 0.05) (Table 1).
In the ROC analysis performed to determine a cut-off point for
DC value between the control, stage1 and stage 2 CKD groups
nd stage 3, stage 4 and stage 5 CKD groups; sensitivity, speciﬁcity,
ositive predictive value and negative predictive value were found
o be 75.44%, 69.81%, 72.88% and 72.55%, respectively in detecting
tage 3, stage 4 and stage 5 CKD among the cases with an ADC value
f 1151 and lower. The area under the ROC curve was  calculated to
e 75.2% and standard error was 4.7%.
A statistically signiﬁcantly negative correlation by 31.6% was
ound between serum creatinine values and ADC values of the cases
r: − 0.316; p: 0.001) (Table 2).
. Discussion
Diffusion weighted imaging (DWI) is a magnetic resonance
maging (MRI) technique that relies on changes in the diffusion
roperties of water molecules in tissues. DW-MRI is commonly
ccepted in neuroradiology for detecting early cerebral ischemia
nd characterization of cerebral tumors and infections [14]. In
ecent years, technological advances and improvements such as
he development of dedicated surface coils and high amplitude
radients in MRI  technique have drawn increasing interest in the
otential clinical role of DW-MRI in non-invasive evaluation of
xtracranial organs [15]. As CKD is a growing health problem, physi-
ians must be equipped to diagnose this patient population [16].
owever, there are typically no clinical signs or symptoms for the
arly diagnosis of CKD patients especially early stages [17]. In the
nited States, based on data from the 1999–2006 National Health
nd Nutrition Examination Survey (NHANES) study, an estimated
1.1 percent (22.4 million) of adults have early stage CKD (CKD
tages 1–3). Among adults with CKD stages 1–3, approximately half
ave either stage 1 or 2 CKD, and half have stage 3 CKD [18]. An
dditional 0.8 million U.S. adults have CKD stage 4, and more than
.3 million have stage 5 CKD and receive hemodialysis [19]. As the
ain renal functions are associated with diffusion of water such as
lomerular ﬁltration, tubular reabsorption, and secretion; DW-MRI
an play an important role in the evaluation of renal function [20].
ecently, the role of ADC values in the evaluation of kidney func-
ion has become a subject of multiple researches [7–11]. However,
nly a few cut-off ADC values have ever been reported to determine
enal dysfunction.
Namimoto et al. [21] reported that ADC values in both the cortex
nd the medulla of the kidneys of acute and chronic kidney disease
atients were signiﬁcantly lower than the values in normal pop-
lation. Xu, et al. [9] found a liner correlation between renal ADC
alues and stages of CKD (r = −0.492, P = 0.000) using b-values rang-
ng from 0 to 500 s/mm2. The authors indicated that the ADC values
f kidneys were signiﬁcantly lower than normal at most stages of
KD, except CKD 1; however, they did not report the difference
etween the ADC values of different stages of CKD. Goyal, et al. [11]
eported that the mean ADC values of different stages of CKD were of Radiology Open 3 (2016) 8–11
signiﬁcantly different from each other and showed a decreasing
trend with increasing stage using b-values ranging between 0 and
500 s/mm2. They found that mean ADC values for stage- 3; stage- 4,
and stage- 5 was  2.2964 ± 0.1243 (×10−3 mm2/s), 1.8413 ± 0.2117
(×10−3 mm2/s), and 1.5218 ± 0.1853 (×10−3 mm2/s), respectively.
The difference was statistically signiﬁcant between stage- 3 and
stage- 4 disease, as well as between stage- 4 and stage- 5 disease
(P = 0.003 and 0.05, respectively). They did not have any patient
with stage-1 and -2 CKD; therefore, the difference between ADC
values of stage-1 and stage-2 CKD was not evaluated. For similar
cut-off GFR values, Toya, et al. [10] found a signiﬁcant difference
between stage-4 and -5 CKD using b-values of 50 and 1000 s/mm2.
However, they did not ﬁnd a difference between stage-3 and -4
CKD. Different from most of the previous researches, stage 1 and
stage 2 CKD patients were included in our study. We  found a signiﬁ-
cant linear correlation between renal parenchymal ADC  values and
different stages of CKD patients using b-values of 0 and 400 s/mm2.
The mean ADC values showed a decreasing trend with increasing
CKD stage (p ≤ 0.001). However, lower cut-off values were obtained
in our study than that in the other studies reported in the literature.
This may  be explained by the fact that the ADC values were mea-
sured in the renal parenchyma without any preference for cortex
or medulla in our study, as it might be difﬁcult to correctly position
the ROI in these areas, as in the study performed by Goyal et al. [11].
Calculated ADC measurements depend on the b value, and lack of
consensus has made it difﬁcult to compare cut-off values of differ-
ent studies and to determine standardized ADC values for different
stages of CKD [10]. Similar to our study, Xu, et al. [9] and Goyal,
et al. [11] found a negative correlation between renal parenchyma
ADC values and serum creatinine levels.
Our study has some limitations. First, ADC values were mea-
sured manually. Manual measurements involve a degree of
subjectivity. Therefore, automated ROI delineation methods with
better accuracy are needed. Second, ADC values depend on the b
values, and lack of consensus has made it difﬁcult to compare the
results of different studies and to generate standardized ADC val-
ues for CKD. Serum creatinine levels can also be affected by some
factors such as dehydration, edema, infections, and drugs.
We conclude that ADC values can play a role in the evaluation
of renal dysfunction. Cut off values that we  obtained may  be useful
for stage 3 CKD patients that classiﬁed in early stages of disease and
respond to treatment. However, population-and protocol-based
(static magnetic ﬁelds, gradients, coils, b factors, use of acceleration
techniques, etc.) cut-off ADC values are needed to identify renal
dysfunction and to distinguish between different stages of CKD,
especially early stages of the disease (CKD stages 1–3). Therefore,
larger scale MRI  studies are needed for conﬁrmation.
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